We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
-13.4%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$85.2M
AUM Growth
+$2.64M
Cap. Flow
+$15.1M
Cap. Flow %
17.68%
Top 10 Hldgs %
80.3%
Holding
25
New
8
Increased
5
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$8.27M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.99M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$5.77M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$5.06M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$10.8M
2
VRNA
Verona Pharma
VRNA
+$10.3M
3
VRDN icon
Viridian Therapeutics
VRDN
+$4.8M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$4.24M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$2.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.63B
$10.4M 12.25%
183,105
+91,692
+100% +$5.06M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.54B
$9.12M 10.7%
266,961
– –
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.12M 10.7%
+175,000
New +$10.2M
AXSM icon
4
Axsome Therapeutics
AXSM
$11.8B
$7.73M 9.07%
+110,600
New +$8.27M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$6.92M 8.12%
+181,805
New +$7.99M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$6.58M 7.72%
223,382
– –
MRUS
7
DELISTED
Merus
MRUS
$5.22M 6.13%
221,384
+22,163
+11% +$537K
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$1.99B
$4.99M 5.86%
+272,690
New +$5.77M
GERN icon
9
Geron
GERN
$911M
$4.71M 5.53%
2,221,639
+98,477
+5% +$267K
ARDX icon
10
Ardelyx
ARDX
$1.29B
$3.6M 4.22%
+881,356
New +$3.44M
AMAM
11
DELISTED
Ambrx Biopharma Inc
AMAM
$3.23M 3.79%
+281,089
New +$3.83M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.06M 3.59%
+70,283
New +$2.51M
JSPR icon
13
Jasper Therapeutics
JSPR
$27.6M
$2.2M 2.58%
314,416
+62,693
+25% +$765K
BDTX icon
14
Black Diamond Therapeutics
BDTX
$103M
$1.82M 2.14%
634,191
-165,809
-21% -$611K
PRAX icon
15
Praxis Precision Medicines
PRAX
$8.7B
$1.81M 2.12%
70,425
-142,908
-67% -$2.7M
CMPX icon
16
Compass Therapeutics
CMPX
$375M
$1.8M 2.11%
914,630
– –
CNTX icon
17
Context Therapeutics
CNTX
$55.7M
$1.1M 1.29%
725,951
+72,555
+11% +$82.1K
PMN icon
18
ProMIS Neurosciences
PMN
$135M
$1.05M 1.24%
+21,277
New +$1.38M
MDVL
19
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$707K 0.83%
117,897
-1
-0% -$10
MDXH icon
20
MDxHealth
MDXH
$21.4M
– –
-349,552
Closed -$1.19M
RPID icon
21
Rapid Micro Biosystems
RPID
$108M
– –
-403,284
Closed -$403K
VRDN icon
22
Viridian Therapeutics
VRDN
$2.04B
– –
-201,752
Closed -$4.8M
VRNA
23
DELISTED
Verona Pharma
VRNA
– –
-487,631
Closed -$10.3M
MRNS
24
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-390,418
Closed -$4.24M
RETA
25
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-105,558
Closed -$10.8M

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q3 2023 Portfolio in Review

As of Q3 2023, Ally Bridge Group held 25 positions worth $85.2M, up 3.2% from $82.6M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Ally Bridge Group deployed $15.1M of net new capital in Q3 2023, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 175,000 shares worth $9.12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $2.7M trimmed.

  • Ally Bridge Group's largest Q3 2023 buy was Intra-Cellular Therapies Inc.: 175,000 shares worth $9.12M.
  • Ally Bridge Group added most to MoonLake Immunotherapeutics in Q3 2023, an estimated $5.06M increase.
  • Ally Bridge Group's biggest Q3 2023 reduction was Praxis Precision Medicines, cutting an estimated $2.7M.
  • Ally Bridge Group fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $10.8M.
  • Ally Bridge Group's ten largest holdings make up 80% of its $85.2M portfolio in Q3 2023.
  • Ally Bridge Group opened 8 new positions and closed 6 in Q3 2023.
  • Ally Bridge Group's portfolio value rose 3.2% quarter-over-quarter to $85.2M.

Based on Ally Bridge Group's 13F filing for Q3 2023, filed 14 Nov 2023.